Moderna’s New European Team Readies For COVID-19 Vaccine D-Day
Gearing Up For A Huge Commercial And Manufacturing Challenge
After a stunning first efficacy readout for its mRNA-based vaccine, the biotech company's leaders in Europe talk about their rapid commercial and manufacturing scale-up.
You may also be interested in...
A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.
Moderna’s stunning interim results add to the world’s relief brought by Pfizer’s first read-out, and also provide the US biotech with the commercial platform it needed
Roche is looking to challenge AstraZeneca's dominance in PNH with its subcutaneously administered once-a-month treatment but could struggle to rival the company's and Novartis’s oral therapy.